Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian CancerH. Gunqor, Hani Gabra, Roshan Agarwal et al.|European Journal of Cancer|2011Cited by 1